A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...

A judge rejected Johnson & Johnson’s $10 billion proposal to end tens of thousands of lawsuits alleging that its products ...

Corcept's Phase III trial of relacorilant with nab-paclitaxel has met its primary endpoint, demonstrating an improvement in ...

Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and ...

A U.S. bankruptcy court judge has denied Johnson & Johnson’s settlement plan related to baby powder containing talc, ...

A second phase 1 trial plans to evaluate CER-1236, a novel chimeric antigen receptor therapy, for solid tumors.

A U.S. bankruptcy judge ruled against the company's attempt to settle tens of thousands of claims alleging its talc products ...

Kunle Odunsi has been named the speaker for the University of Chicago’s Convocation ceremony on June 7. A renowned expert in ...

Johnson & Johnson shares fell more than 3% on Tuesday after a U.S. bankruptcy judge rejected its $10 billion proposal to end ...

A U.S. bankruptcy judge on Monday rejected Johnson & Johnson's $10 billion proposal to end lawsuits alleging that its baby ...